Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FTY720 (fingolimod) in renal transplantation.

Klemens Budde1, Manuela Schütz, Petra Glander

  • 1Department of Nephrology, Charité Universitatsmedizin Berlin, Berlin, Germany. klemens.budde@charite.de

Clinical Transplantation
|November 15, 2006
PubMed
Summary

FTY720 (Fingolimod), a sphingosine 1-phosphate receptor modulator, shows promise for autoimmune diseases like multiple sclerosis but failed in renal transplantation due to efficacy and safety concerns.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Confronted with the real world: how final-year medical students experience interprofessional collaboration in clinical practice.

BMC medical education·2026
Same author

Unheard Voices from Earth: A Fable from 2184.

Medical education·2025
Same author

[Organize teaching in the surgical rotation -What practical experience do students starting the final year clerkship have?]

Chirurgie (Heidelberg, Germany)·2025
Same author

From professional tasks to contexts: A consensus study on chief complaints as clinical anchors for EPAs for entry into residency.

Medical teacher·2025
Same author

ASPIRE-to-excellence: A framework for developing innovative and inspirational approaches to health professions education.

Medical teacher·2025
Same author

Mapping the undergraduate medical curriculum of the Charité Berlin against the National Competence-Based Catalogue of Learning Objectives (NKLM 2.0).

GMS journal for medical education·2025

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation

Background:

  • FTY720 (Fingolimod) is a novel immunomodulator and the first sphingosine 1-phosphate receptor (S1P-R) modulator.
  • Its mechanism differs from traditional immunosuppressants, acting as a sphingosine analogue.

Purpose of the Study:

  • To review FTY720's mechanism of action, preclinical data, and clinical development.
  • To assess its efficacy and safety in transplantation and multiple sclerosis.

Main Methods:

  • Review of preclinical models and clinical trial data.
  • Pharmacokinetic and pharmacodynamic analysis of FTY720.
  • Evaluation of lymphocyte sequestration and adverse events.

Main Results:

Related Experiment Videos

  • FTY720 prolonged allograft survival in preclinical models.
  • Clinical trials showed transient bradycardia and decreased lymphocyte counts.
  • FTY720 failed to improve renal allograft rejection prevention and caused renal impairment and macular edema.
  • Initial studies suggest high efficacy in multiple sclerosis.

    • Conclusions:

    • FTY720 development was halted for renal transplantation due to lack of efficacy and adverse events.
    • Further investigation in multiple sclerosis is ongoing, potentially offering new therapeutic options for demyelinating diseases.